Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

Authors:

Abstract
Historically, the outcome of patients with stage III melanoma was poor with a high risk of relapse.1,2 Adjuvant therapy with monoclonal antibodies targeting cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) and adjuvant therapies targeting BRAF and MEK have improved the relapse-free survival (RFS). Still, 40% to 50% of patients with high-risk stage III melanoma relapse within 3 to 5 years.3-5 Results of early clinical trials show that neoadjuvant therapy with checkpoint inhibitors induces high pathologic response rates, especially with the combination of anti-PD-1 and anti-CTLA-4 antibodies, with subsequent durable RFS outcomes that may outperform adjuvant therapy.6-8

This publication has 29 references indexed in Scilit: